Trican Biotechnology Co., Ltd.

Industrial Technology Research Institute

Li-Tsen Lin

Huang-Tsu Chen

Jiun-Shyang Leou

Yun-Ting Wang

Cheng-Ke Li

Chung-Yuan Hsu

Min-Yuan Chou

Ya-Ping Lai

Mei-Wei Lin

Chung-Yuan Sun

Ssu-Yuan Wu

Shiou-Ting Chen

Chin-Pen Lai

Chen-Wei Chiang

The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Anti-angiogenesis fusion protein and uses thereof

Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Anti-TIGIT antibodies and methods of use

The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.

Human anti-CD47 antibodies and uses thereof

Growing community of inventors

Taipei, Taiwan

Li-Tsen Lin